Q-omics provides the consensus-scored CDY7P profile across patient tissues and cancer cell-line models. CDY7P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CDY7P is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, CDY7P RNA expression shows 5,013 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, KIRC, and STAD as cancer lineages where CDY7P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDY7P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDY7P survival associations across molecular data types. CDY7P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDY7P RNA expression–survival associations across cancer types. High CDY7P expression shows unfavorable associations in KIRP, UCS, COAD, PCPG and SKCM, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CDY7P RNA expression.
This table summarizes CDY7P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CDY7P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDY7P shows lower tumor expression in KIRC, KICH, THCA and LIHC and higher tumor expression in STAD. The KIRC box plot shows higher CDY7P RNA expression in normal versus tumor tissue (log2 FC = −0.010, t-test p = .010).
This table shows molecular features associated with CDY7P in patient tissues and cancer cell lines. In patient samples, CDY7P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
